[{"orgOrder":0,"company":"Royal DSM","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Nutrasource","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Nutrasource"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Nutrasource"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Syneos Health"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Royal DSM \/ Humanetics","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Humanetics"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BELGIUM","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"9","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"10","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"National Liver Institute, Egypt | Cairo University | High Institute of Public Health, Egypt","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Arachidonic Acid","moa":"Prostaglandin G\/H synthase 1 (COX-1)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ National Liver Institute, Egypt | Cairo University | High Institute of Public Health, Egypt","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ National Liver Institute, Egypt | Cairo University | High Institute of Public Health, Egypt"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Analyze & Realize"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Spaulding Clinical, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Royal DSM \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SINGAPORE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Beta-Cryptoxanthin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Glycemic Index Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcium Propionate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Glycemic Index Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Glycemic Index Laboratories"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Cognivida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Cognivida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"DHA-O","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Fish Oil Ethyl Ester","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fortified Maize Porridge","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Fruitflow","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Fruitflow-Ii","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharides 2\\'-Ofucosyllactose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Humiome Post Lb","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ KGK Science"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Humiome Post LB","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Analyze & Realize"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Hy.D Calcifediol","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Adare Biome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Acquisition","leadProduct":"Lactobacillus LB","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Royal DSM","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"15","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Universiteit Antwerpen","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Limosilactobacillus reuteri AMBV339","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Universiteit Antwerpen","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Universiteit Antwerpen"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Lumivida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Lutein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Micronutrient","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Nutritional Beverage Fortified With Lutein","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Abbott Laboratories"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Oatwell28 Oatwell Original Powder","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Olive Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Or\u00e9vida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Porridge Fortified","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Pro-\/Prebiotic Mix","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Pufa","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"University of Zurich | Tufts University","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ University of Zurich | Tufts University","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ University of Zurich | Tufts University"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Leatherhead Food Research","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Leatherhead Food Research","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Leatherhead Food Research"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FINLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"Royal DSM \/ Royal DSM","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Royal DSM"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Carol Fabian","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Neurology","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Carol Fabian","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Carol Fabian"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Sofya Pintova","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Sofya Pintova","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Sofya Pintova"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Carol Fabian","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Carol Fabian","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Carol Fabian"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Naga P. Chalasani","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Vitamin E","moa":"SEC14-like protein 4; SEC14-like protein 3; SEC14-like protein 2; Nuclear receptor subfamily 1 group I member 2; Protein kinase C beta type; Polyunsaturated fatty acid 5-lipoxygenase; Protein kinase C alpha type; Diacylglycerol kinase alpha; Serine\/threonine-protein phosphatase 2A catalytic subunit beta isoform; Serine\/threonine-protein phosphatase 2A catalytic subunit alpha isoform","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Naga P. Chalasani","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Naga P. Chalasani"}]

Find Clinical Drug Pipeline Developments & Deals by Royal DSM

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Humiome Post LB is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Aging.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 08, 2025

                          Lead Product(s) : Humiome Post LB

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Analyze & Realize

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Riboflavin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Dysbiosis.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          July 30, 2025

                          Lead Product(s) : Riboflavin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Analyze & Realize

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Humiome Post Lb is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          April 22, 2025

                          Lead Product(s) : Humiome Post Lb

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : KGK Science

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Human Milk Oligosaccharides 2'-Ofucosyllactose is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 21, 2025

                          Lead Product(s) : Human Milk Oligosaccharides 2\'-Ofucosyllactose

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 29, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Nutrasource

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Vitamin C is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 24, 2024

                          Lead Product(s) : Ascorbic Acid

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Nutrasource

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Limosilactobacillus reuteri AMBV339 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 22, 2024

                          Lead Product(s) : Limosilactobacillus reuteri AMBV339

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Universiteit Antwerpen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Vitamin D is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Vitamin D Deficiency.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          October 23, 2023

                          Lead Product(s) : Vitamin D

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Recipient : Instituto Nacional de Salud Publica, Mexico

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The acquisition will facilitate DSM to anticipate in the rapidly extension of the availability of Lacteol (lactobacillus LB), an effective postbiotic treatment for diarrhea, engineered using adare's innovative microbiome technology platform, for people t...

                          Product Name : Lacteol

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          April 19, 2023

                          Lead Product(s) : Lactobacillus LB

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Recipient : Adare Biome

                          Deal Size : $302.8 million

                          Deal Type : Acquisition

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Riboflavin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          April 07, 2023

                          Lead Product(s) : Riboflavin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank